4-[2-(2-溴苯基)-5-(4-氟苯基)-1H-咪唑-4-基]吡啶 | 384820-17-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-[2-(2-溴苯基)-5-(4-氟苯基)-1H-咪唑-4-基]吡啶
• 中文别名: 4-[2-(2-溴苯基)-4-(4-氟苯基)-1H-咪唑-5-基]吡啶
• 英文名称: 4-[2-(2-bromophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyridine
• CAS: 384820-17-1
• 化学式: C₂₀H₁₃BrFN₃
• 分子量: 394.246
• InChiKey: COVWDRBCMJOSQM-UHFFFAOYSA-N

物化性质

• 沸点：
  556.1±50.0 °C(Predicted)
• 密度：
  1.457

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-氟-n-甲氧基-n-甲基苯甲酰胺 在 copper diacetate 、 ammonium acetate 、 溶剂黄146 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 4-[2-(2-溴苯基)-5-(4-氟苯基)-1H-咪唑-4-基]吡啶
  参考文献：
  名称：

  Substituted Imidazoles as Glucagon Receptor Antagonists

  摘要：

  A modestly active, nonselective triarylimidazole lead was optimized for binding affinity with the human glucagon receptor. This led to the identification of a 2- and/or 4-alkyl or alkyloxy substituent on the imidazole C4-aryl group as a structural determinant for significant enhancement in binding with the glucagon receptor (e.g., 41, IC50 = 0.053 muM) and selectivity (> 1000x) over p38 MAP kinase in this class of compounds. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00498-x

文献信息

• [EN] 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS<br/>[FR] INHIBITEURS DE LA CASÉINE KINASE 1 À BASE D'AZOLE 2,4,5-TRI-SUBSTITUÉ EN TANT QU'INDUCTEURS DE LA CARDIOMYOGENÈSE
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2015119579A1

  公开（公告）日：2015-08-13

  This invention relates to a method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof wherein R1, R2 and R3 independently from another represent hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl; X represents NR4, O or S; and R4 represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl. The method can be used in the late phase of stem cell differentiation and in the compounds of formula (I) or (II) in combination with other small molecules can lead to especially high differentiation of stem cells into cardiomyocytes. The invention further relates to novel compounds which can be used in the method of the invention and kits for stem cell differentiation.

  本发明涉及一种通过酪蛋白激酶1抑制诱导或增强多能干细胞向心肌细胞分化的方法，所述方法包括将干细胞培养在含有式(I)或(II)的酪蛋白激酶1抑制剂的培养基中，或其立体异构体、互变异构体或盐中，其中R1、R2和R3独立地表示氢、可选择地取代的烷基、烯烃基、炔烃基、杂环基、杂芳基或芳基；X表示NR4、O或S；R4表示氢、可选择地取代的烷基、烯烃基、炔烃基、杂环基、杂芳基或芳基。该方法可用于干细胞分化的后期阶段，结合式(I)或(II)的化合物与其他小分子一起可导致干细胞特别高效地分化为心肌细胞。该发明还涉及可用于该方法的新化合物以及用于干细胞分化的试剂盒。
• Substituted 3-alkyl and 3-alkenyl azetidine derivatives
  申请人：Baker K. Robert

  公开号：US20060293299A1

  公开（公告）日：2006-12-28

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或逆拮抗剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可作为中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和吉兰-巴雷综合征）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。该化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US10865384B2

  公开（公告）日：2020-12-15

  This invention relates to a method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof wherein R1, R2 and R3 independently from another represent hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl; X represents NR4, O or S; and R4 represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl. The method can be used in the late phase of stem cell differentiation and in the compounds of formula (I) or (II) in combination with other small molecules can lead to especially high differentiation of stem cells into cardiomyocytes. The invention further relates to novel compounds which can be used in the method of the invention and kits for stem cell differentiation.

  本发明涉及一种通过抑制酪蛋白激酶1诱导或增强多能干细胞向心肌细胞分化的方法，所述方法包括在含有式(I)或(II)的酪蛋白激酶1抑制剂或其立体异构体、同系物或盐的培养基存在下培养干细胞，其中R1、R2和R3独立地代表氢、任选取代的烷基、烯基、炔基、杂环基、杂芳基或芳基；X 代表 NR4、O 或 S；R4 代表氢、任选取代的烷基、烯基、炔基、杂环基、杂芳基或芳基。该方法可用于干细胞分化的后期阶段，式（I）或（II）化合物与其他小分子结合使用，可使干细胞分化为心肌细胞的程度特别高。本发明进一步涉及可用于本发明方法和干细胞分化试剂盒的新型化合物。
• 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US20170166867A1

  公开（公告）日：2017-06-15

  This invention relates to a method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof wherein R 1 , R 2 and R 3 independently from another represent hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl; X represents NR 4 , O or S; and R 4 represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl. The method can be used in the late phase of stem cell differentiation and in the compounds of formula (I) or (II) in combination with other small molecules can lead to especially high differentiation of stem cells into cardiomyocytes. The invention further relates to novel compounds which can be used in the method of the invention and kits for stem cell differentiation.
• [EN] INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3<br/>[FR] INHIBITEURS DE GLYCOGENE SYNTHASE KINASE-3
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003024447A1

  公开（公告）日：2003-03-27

  The present invention relates generally to inhibitors of the serine/threoine kinase GSK3, and more particularly to triarylimidazole compounds of the following formula (I):